Cancer vaccines from cryogenically silicified tumour cells functionalized with pathogen-associated molecular patterns

Efficacious cancer vaccines can be made via the cryogenic silicification of tumour cells followed by the decoration of the silicified surface with pathogen-associated molecular patterns. The production of personalized cancer vaccines made from autologous tumour cells could benefit from mechanisms that enhance immunogenicity. Here we show that cancer vaccines can be made via the cryogenic silicification of tumour cells, which preserves tumour antigens within nanoscopic layers of silica, followed by the decoration of the silicified surface with pathogen-associated molecular patterns. These pathogen-mimicking cells activate dendritic cells and enhance the internalization, processing and presentation of tumour antigens to T cells. In syngeneic mice with high-grade ovarian cancer, a cell-line-based silicified cancer vaccine supported the polarization of CD4(+) T cells towards the T-helper-1 phenotype in the tumour microenvironment, and induced tumour-antigen-specific T-cell immunity, resulting in complete tumour eradication and in long-term animal survival. In the setting of established disease and a suppressive tumour microenvironment, the vaccine synergized with cisplatin. Silicified and surface-modified cells from tumour samples are amenable to dehydration and room-temperature storage without loss of efficacy and may be conducive to making individualized cancer vaccines across tumour types.

Automated summary

Efficient cancer vaccines can be created by cryogenic silicification of tumor cells followed by decorating the surface with pathogen-related molecular patterns, leading to activation of dendritic cells and enhanced T cell immune responses against tumor antigens.